Not Found
Locations

Find information on medical topics, symptoms, drugs, procedures, news and more, written for the health care professional.

Chronic Obstructive Pulmonary Disease (COPD)

By Robert A. Wise, MD, Professor of Medicine, Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine

Click here for
Patient Education

Take our short survey

Chronic obstructive pulmonary disease (COPD) is airflow limitation caused by an inflammatory response to inhaled toxins, often cigarette smoke. Alpha-1 antitrypsin deficiency and various occupational exposures are less common causes in nonsmokers. Symptoms are productive cough and dyspnea that develop over years; common signs include decreased breath sounds, prolonged expiratory phase of respiration, and wheezing. Severe cases may be complicated by weight loss, pneumothorax, frequent acute decompensation episodes, right heart failure, and/or acute or chronic respiratory failure. Diagnosis is based on history, physical examination, chest x-ray, and pulmonary function tests. Treatment is with bronchodilators, corticosteroids, and, when necessary, oxygen and antibiotics. About 50% of patients with severe COPD die within 10 yr of diagnosis.

COPD comprises

  • Chronic obstructive bronchitis (clinically defined)

  • Emphysema (pathologically or radiologically defined)

Many patients have features of both.

Chronic obstructive bronchitis is chronic bronchitis with airflow obstruction. Chronic bronchitis is defined as productive cough on most days of the week for at least 3 mo total duration in 2 successive years. Chronic bronchitis becomes chronic obstructive bronchitis if spirometric evidence of airflow obstruction develops. Chronic asthmatic bronchitis is a similar, overlapping condition characterized by chronic productive cough, wheezing, and partially reversible airflow obstruction; it occurs predominantly in smokers with a history of asthma. In some cases, the distinction between chronic obstructive bronchitis and chronic asthmatic bronchitis is unclear and may be referred to as asthma COPD overlap syndrome (ACOS).

Emphysema is destruction of lung parenchyma leading to loss of elastic recoil and loss of alveolar septa and radial airway traction, which increases the tendency for airway collapse. Lung hyperinflation, airflow limitation, and air trapping follow. Airspaces enlarge and may eventually develop blebs or bullae.

Epidemiology

In the US, about 24 million people have airflow limitation, of whom about 12 million have a diagnosis of COPD. COPD is the 3rd leading cause of death, resulting in 135,000 deaths in 2010—compared with 52,193 deaths in 1980. From 1980 to 2000, the COPD mortality rate increased 64% (from 40.7 to 66.9/100,000) and has remained steady since then. Prevalence, incidence, and mortality rates increase with age. Prevalence is now higher in women, but total mortality is similar in both sexes. COPD seems to aggregate in families independent of alpha-1 antitrypsin deficiency (alpha-1antiprotease inhibitor deficiency).

COPD is increasing worldwide because of the increase in smoking in developing countries, the reduction in mortality due to infectious diseases, and the widespread use of biomass fuels such as wood, grasses, or other organic materials. COPD mortality may also affect developing nations more than developed nations. COPD affects 64 million people and caused > 3 million deaths worldwide in 2005 and is projected to become the 3rd leading cause of death globally by the year 2030.

Etiology

There are several causes of COPD:

  • Smoking (and less often other inhalational exposures)

  • Genetic factors

Inhalational exposure

Of all inhalational exposures, cigarette smoking is the primary risk factor in most countries, although only about 15% of smokers develop clinically apparent COPD; an exposure history of 40 or more pack-years is especially predictive. Smoke from indoor cooking and heating is an important causative factor in developing countries. Smokers with preexisting airway reactivity (defined by increased sensitivity to inhaled methacholine), even in the absence of clinical asthma, are at greater risk of developing COPD than are those without.

Low body weight, childhood respiratory disorders, and exposure to passive cigarette smoke, air pollution, and occupational dust (eg, mineral dust, cotton dust) or inhaled chemicals (eg, cadmium) contribute to the risk of COPD but are of minor importance compared with cigarette smoking.

Genetic factors

The best-defined causative genetic disorder is alpha-1 antitrypsin deficiency, which is an important cause of emphysema in nonsmokers and influences susceptibility to disease in smokers.

In recent years, > 30 genetic variants have been found to be associated with COPD or decline in lung function in selected populations, but none has been shown to be as consequential as alpha-1 antitrypsin.

Pathophysiology

Various factors cause the airflow limitation and other complications of COPD.

Inflammation

Inhalational exposures can trigger an inflammatory response in airways and alveoli that leads to disease in genetically susceptible people. The process is thought to be mediated by an increase in protease activity and a decrease in antiprotease activity. Lung proteases, such as neutrophil elastase, matrix metalloproteinases, and cathepsins, break down elastin and connective tissue in the normal process of tissue repair. Their activity is normally balanced by antiproteases, such as alpha-1 antitrypsin, airway epithelium–derived secretory leukoproteinase inhibitor, elafin, and matrix metalloproteinase tissue inhibitor. In patients with COPD, activated neutrophils and other inflammatory cells release proteases as part of the inflammatory process; protease activity exceeds antiprotease activity, and tissue destruction and mucus hypersecretion result.

Neutrophil and macrophage activation also leads to accumulation of free radicals, superoxide anions, and hydrogen peroxide, which inhibit antiproteases and cause bronchoconstriction, mucosal edema, and mucous hypersecretion. Neutrophil-induced oxidative damage, release of profibrotic neuropeptides (eg, bombesin), and reduced levels of vascular endothelial growth factor may contribute to apoptotic destruction of lung parenchyma.

The inflammation in COPD increases as disease severity increases, and, in severe (advanced) disease, inflammation does not resolve completely despite smoking cessation. This chronic inflammation does not seem to respond to corticosteroids.

Infection

Respiratory infection (which COPD patients are prone to) may amplify progression of lung destruction.

Bacteria, especially Haemophilus influenzae, colonize the lower airways of about 30% of patients with COPD. In more severely affected patients (eg, those with previous hospitalizations), colonization with Pseudomonas aeruginosa or other gram-negative bacteria is common. Smoking and airflow obstruction may lead to impaired mucus clearance in lower airways, which predisposes to infection. Repeated bouts of infection increase the inflammatory burden that hastens disease progression. There is no evidence, however, that long-term use of antibiotics slows the progression of COPD.

Airflow limitation

The cardinal pathophysiologic feature of COPD is airflow limitation caused by airway narrowing and/or obstruction, loss of elastic recoil, or both.

Airway narrowing and obstruction are caused by inflammation-mediated mucus hypersecretion, mucus plugging, mucosal edema, bronchospasm, peribronchial fibrosis, and destruction of small airways or a combination of these mechanisms. Alveolar septa are destroyed, reducing parenchymal attachments to the airways and thereby facilitating airway closure during expiration.

Enlarged alveolar spaces sometimes consolidate into bullae, defined as airspaces 1 cm in diameter. Bullae may be entirely empty or have strands of lung tissue traversing them in areas of locally severe emphysema; they occasionally occupy the entire hemithorax. These changes lead to loss of elastic recoil and lung hyperinflation.

Increased airway resistance increases the work of breathing. Lung hyperinflation, although it decreases airway resistance, also increases the work of breathing. Increased work of breathing may lead to alveolar hypoventilation with hypoxia and hypercapnia, although hypoxia is also caused by ventilation/perfusion (V/Q) mismatch.

Complications

In addition to airflow limitation and sometimes respiratory insufficiency, complications include

  • Pulmonary hypertension

  • Respiratory infection

  • Weight loss and other comorbidities

Chronic hypoxemia increases pulmonary vascular tone, which, if diffuse, causes pulmonary hypertension and cor pulmonale. The increase in pulmonary vascular pressure may be augmented by the destruction of the pulmonary capillary bed due to destruction of alveolar septa.

Viral or bacterial respiratory infections are common among patients with COPD and cause a large percentage of acute exacerbations. It is currently thought that acute bacterial infections are due to acquisition of new strains of bacteria rather than overgrowth of chronic colonizing bacteria.

Weight loss may occur, perhaps in response to decreased caloric intake and increased levels of circulating tumor necrosis factor (TNF)-alpha.

Other coexisting or complicating disorders that adversely affect quality of life and survival include osteoporosis, depression, anxiety, coronary artery disease, lung cancer and other cancers, muscle atrophy, and gastroesophageal reflux. The extent to which these disorders are consequences of COPD, smoking, and the accompanying systemic inflammation is unclear.

Symptoms and Signs

COPD takes years to develop and progress. Most patients have smoked 20 cigarettes/day for > 20 yr.

  • Productive cough usually is the initial symptom, developing among smokers in their 40s and 50s.

  • Dyspnea that is progressive, persistent, exertional, or worse during respiratory infection appears when patients are in their late 50s or 60s.

Symptoms usually progress quickly in patients who continue to smoke and in those who have a higher lifetime tobacco exposure. Morning headache develops in more advanced disease and signals nocturnal hypercapnia or hypoxemia.

Signs of COPD include wheezing, a prolonged expiratory phase of breathing, lung hyperinflation manifested as decreased heart and lung sounds, and increased anteroposterior diameter of the thorax (barrel chest). Patients with advanced emphysema lose weight and experience muscle wasting that has been attributed to immobility, hypoxia, or release of systemic inflammatory mediators, such as TNF-alpha.

Signs of advanced disease include pursed-lip breathing, accessory respiratory muscle use, paradoxical inward movement of the lower intercostal interspaces during inspiration (Hoover sign), and cyanosis. Signs of cor pulmonale include neck vein distention, splitting of the 2nd heart sound with an accentuated pulmonic component, tricuspid insufficiency murmur, and peripheral edema. Right ventricular heaves are uncommon in COPD because the lungs are hyperinflated.

Spontaneous pneumothorax may occur (possibly related to rupture of bullae) and should be suspected in any patient with COPD whose pulmonary status abruptly worsens.

Acute exacerbations

Acute exacerbations occur sporadically during the course of COPD and are heralded by increased symptom severity. The specific cause of any exacerbation is almost always impossible to determine, but exacerbations are often attributed to viral URIs, acute bacterial bronchitis, or exposure to respiratory irritants. As COPD progresses, acute exacerbations tend to become more frequent, averaging about 1 to 3 episodes/yr.

Diagnosis

  • Chest x-ray

  • Pulmonary function testing

Diagnosis is suggested by history, physical examination, and chest imaging and is confirmed by pulmonary function tests. Similar symptoms can be caused by asthma, heart failure, and bronchiectasis (see Table: Differential Diagnosis of COPD). COPD and asthma are sometimes easily confused and may overlap (called asthma-COPD overlap syndrome, or ACOS).

Differential Diagnosis of COPD

Diagnosis

Onset

Imaging Results

Other Features

COPD

Middle age

Sometimes lung hyperinflation, bullae, increased retrosternal air space, and/or bronchial wall thickening (seen on chest x-ray); however, usually not helpful diagnostically and done mainly to exclude other disorders

Slowly progressive symptoms

History of smoking or exposure to tobacco or other types of smoke

Early in life (often during childhood)

Usually normal, possibly hyperinflation or segmental atelectasis

Symptoms vary widely from day to day

Symptoms often worse at night or early morning

History of allergies, rhinitis, or eczema

Often family history of asthma

All ages, but most often in older or middle age

Bronchial dilation and bronchial wall thickening (seen on chest x-ray or chest CT)

Often large amounts of purulent sputum

Often history of recent bacterial infection

Diffuse panbronchiolitis

Usually between ages 10 and 60 yr (mean age of 40)

Diffuse small centrilobular nodular opacities and hyperinflation seen on chest x-ray and high-resolution CT

Mostly male nonsmokers

Almost all have chronic sinusitis

Predominately in those of Asian descent

All ages, but most often in older or middle age

Enlarged heart, pleural effusion, fluid in major fissure, sometimes pulmonary edema (seen on chest x-ray)

Volume restriction without airflow limitation (detected by pulmonary function tests)

Obliterative bronchiolitis

Onset at younger age

Hypodense areas (seen on CT during expiration)

Nonsmokers who may have a history of rheumatoid arthritis or acute fume exposure

History of lung or bone marrow transplantation

TB

All ages

Lung infiltrates, typically multinodular, sometimes calcified hilar nodes (seen on chest x-ray)

Confirmed by microbiologic testing

Usually in areas with high prevalence of TB

Data adapted from The Global Strategy for the Diagnosis, Management and Prevention of COPD Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2016. Available at http://www.goldcopd.org.

Systemic disorders that may have a component of airflow limitation may suggest COPD; they include HIV infection, abuse of IV drugs (particularly cocaine and amphetamines), sarcoidosis, Sjögren syndrome, bronchiolitis obliterans, lymphangioleiomyomatosis, and eosinophilic granuloma. COPD can be differentiated from interstitial lung diseases (ILD) by chest imaging, which shows increased interstitial markings in ILD, and pulmonary function testing, which shows a restrictive ventilatory defect rather than an obstructive ventilatory defect. In some patients, COPD and ILD coexist (combined pulmonary fibrosis and emphysema [CPFE]) in which lung volumes are relatively preserved, but gas exchange is severely impaired.

Pulmonary function tests

Patients suspected of having COPD should undergo pulmonary function testing to confirm airflow limitation, to quantify its severity and reversibility, and to distinguish COPD from other disorders. Pulmonary function testing is also useful for following disease progression and monitoring response to treatment. The primary diagnostic tests are

  • FEV1:, The volume of air forcefully expired during the first second after taking a full breath

  • Forced vital capacity (FVC): The total volume of air expired with maximal force

  • Flow-volume loops: Simultaneous spirometric recordings of airflow and volume during forced maximal expiration and inspiration

Reductions of FEV1, FVC, and the ratio of FEV1/FVC are the hallmark of airflow limitation. Flow-volume loops show a concave pattern in the expiratory tracing (see Figure: Flow-volume loops.). There are 2 basic pathways by which COPD can develop and manifest with symptoms in later life. In the first, patients may have normal lung function in early adulthood, which is followed by an increased decline in FEV1 (about ≥ 60 mL/yr). With the second pathway, patients have impaired lung function in early adulthood, often associated with asthma or other childhood respiratory disease. In these patients, COPD may present with a normal age-related decline in FEV1 (about 30 mL/yr). Although this 2 pathway model is conceptually helpful, a wide range of individual trajectories is possible (1). When the FEV1 falls below about 1 L, patients develop dyspnea during activities of daily living (although dyspnea is more closely related to the degree of dynamic hyperinflation [progressive hyperinflation due to incomplete exhalation] than to the degree of airflow limitation). When the FEV1 falls below about 0.8 L, patients are at risk of hypoxemia, hypercapnia, and cor pulmonale.

FEV1 and FVC are easily measured with office spirometry and define severity of disease (see Table: Classification and Treatment of COPD) because they correlate with symptoms and mortality. Normal reference values are determined by patient age, sex, and height.

Additional pulmonary function testing is necessary only in specific circumstances, such as before lung volume reduction surgery. Other test abnormalities may include

  • Increased total lung capacity

  • Increased functional residual capacity

  • Increased residual volume

  • Decreased vital capacity

  • Decreased single-breath diffusing capacity for carbon monoxide (DLco)

Findings of increased total lung capacity, functional residual capacity, and residual volume can help distinguish COPD from restrictive pulmonary disease, in which these measures are diminished.

Decreased DLco is nonspecific and is reduced in other disorders that affect the pulmonary vascular bed, such as interstitial lung disease, but can help distinguish emphysema from asthma, in which DLco is normal or elevated.

Classification and Treatment of COPD

Patient Group

Findings

Treatment

Alternative Treatments

All patients

Avoidance of risk factors (eg, smoking)

Influenza vaccine annually

Pneumococcal polysaccharide vaccine

Exercise training as directed by pulmonary rehabilitation

Treatment of complications

A (low risk, few symptoms)

FEV1 ≥ 50% predicted

0–1 exacerbation/yr

mMRC*: 0–1

SABA or SAC, as needed

LAC

or

LABA

or

SABA plus SAC

B (low risk, more symptoms)

FEV1 ≥ 50% predicted

0–1 exacerbation/yr

mMRC ≥ 2

LAC

or

LABA

LABA plus LAC

or

SABA and/or SAC

C (high risk, few symptoms)

FEV1 < 50% predicted

≥ 2 exacerbations/yr

mMRC: 0–1

ICS plus LABA

or

LAC

LABA plus LAC

or

LAC plus PDE4I

or

LABA plus PDE4I

D (high risk, more symptoms)

FEV1 < 50% predicted

≥ 2 exacerbations/yr

mMRC: ≥ 2

ICS plus LABA

and/or

LAC

ICS plus LABA plus LAC

or

ICS plus LABA plus PDE4I

or

LABA plus LAC

or

LAC plus PDE4I

*The COPD Assessment Test (CAT) may be used instead of the mMRC to evaluate symptoms. For MRC definitions, see Table: Breathlessness Measurement using the Modified British Medical Research Council (mMRC) Questionnaire.

FEV1 = forced expiratory volume in 1 sec; ICS = inhaled corticosteroid; LABA = long-acting beta-agonist; LAC = long-acting anticholinergic; mMRC = Breathlessness measurement using the Modified British Medical Research Council (mMRC) Questionnaire; PDE4I = phosphodiesterase-4 inhibitor; SABA = short-acting beta-agonist; SAC = short-acting anticholinergic.

Data from the Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. www.goldcopd.org.

Breathlessness Measurement using the Modified British Medical Research Council (mMRC) Questionnaire

Grade

Shortness of Breath

0

None except during strenuous exercise

1

Occurring when hurrying on level ground or walking up a slight incline

2

Resulting in walking more slowly than people of the same age on level ground

or

Resulting in stopping for breath when walking at own pace on level ground

3

Resulting in stopping for breath after walking about 100 meters or after a few minutes on level ground

4

Severe enough to prevent the person from leaving the house

or

Occurring when dressing or undressing

Adapted from Mahler DA, Wells CK: Evaluation of clinical methods for rating dyspnea. Chest 93:580–586, 1988.

Imaging tests

Chest x-ray may have characteristic findings. In patients with emphysema, changes can include lung hyperinflation manifested as a flat diaphragm (ie, increase in the angle formed by the sternum and anterior diaphragm on a lateral film from the normal value of 45° to > 90°), rapid tapering of hilar vessels, and bullae (ie, radiolucencies >1 cm surrounded by arcuate, hairline shadows). Other typical findings include widening of the retrosternal airspace and a narrow cardiac shadow. Emphysematous changes occurring predominantly in the lung bases suggest alpha-1 antitrypsin deficiency. The lungs may look normal or have increased lucency secondary to loss of parenchyma. Among patients with chronic obstructive bronchitis, chest x-rays may be normal or may show a bibasilar increase in bronchovascular markings as a result of bronchial wall thickening.

Prominent hila suggest large central pulmonary arteries that may signify pulmonary hypertension. Right ventricular enlargement that occurs in cor pulmonale may be masked by lung hyperinflation or may manifest as encroachment of the heart shadow on the retrosternal space or by widening of the transverse cardiac shadow in comparison with previous chest x-rays.

Chest CT may reveal abnormalities that are not apparent on the chest x-ray and may also suggest coexisting or complicating disorders, such as pneumonia, pneumoconiosis, or lung cancer. CT helps assess the extent and distribution of emphysema, estimated either by visual scoring or with analysis of the distribution of lung density. Indications for obtaining CT in patients with COPD include evaluation for lung volume reduction surgery, suspicion of coexisting or complicating disorders that are not clearly evident or excluded by chest x-ray, suspicion of lung cancer, and screening for lung cancer.

Adjunctive tests

Alpha-1 antitrypsin levels should be measured in patients < 50 yr with symptomatic COPD and in nonsmokers of any age with COPD to detect alpha-1 antitrypsin deficiency. Other indications of possible alpha-1 antitrypsin deficiency include a family history of premature COPD or unexplained liver disease, lower-lobe distribution of emphysema, and COPD associated with antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis. If levels of alpha-1 antitrypsin are low, the diagnosis should be confirmed by genetic testing to establish the alpha-1 antitrypsin phenotype.

ECG, often done to exclude cardiac causes of dyspnea, typically shows diffusely low QRS voltage with a vertical heart axis caused by lung hyperinflation and increased P-wave voltage or rightward shifts of the P-wave vector caused by right atrial enlargement in patients with advanced emphysema. Findings of right ventricular hypertrophy include an R or R wave as tall as or taller than the S wave in lead V1; an R wave smaller than the S wave in lead V6; right-axis deviation >110° without right bundle branch block; or some combination of these. Multifocal atrial tachycardia, an arrhythmia that can accompany COPD, manifests as a tachyarrhythmia with polymorphic P waves and variable PR intervals.

Echocardiography is occasionally useful for assessing right ventricular function and pulmonary hypertension, although air trapping makes it technically difficult in patients with COPD. Echocardiography is most often indicated when coexistent left ventricular or valvular heart disease is suspected.

CBC is of little diagnostic value in the evaluation of COPD but may show erythrocythemia (Hct > 48%) if the patient has chronic hypoxemia. Patients with anemia (for reasons other than COPD) have disproportionately severe dyspnea.

Serum electrolytes are of little value but may show an elevated bicarbonate level if patients have chronic hypercapnia.

Evaluation of exacerbations

Patients with acute exacerbations usually have combinations of increased cough, sputum, dyspnea, and work of breathing, as well as low oxygen saturation on pulse oximetry, diaphoresis, tachycardia, anxiety, and cyanosis. Patients with exacerbations accompanied by retention of carbon dioxide may be lethargic or somnolent, a very different appearance.

All patients requiring hospitalization for an acute exacerbation should undergo testing (eg, ABG sampling) to quantify hypoxemia and hypercapnia. Hypercapnia may exist without hypoxemia.

Findings of Pao2< 50 mm Hg or Paco2> 50 mm Hg in patients with respiratory acidemia define acute respiratory failure. However, some patients chronically manifest such levels of Pao2 and Paco2 in the absence of acute respiratory failure.

A chest x-ray is often done to check for pneumonia or pneumothorax. Very rarely, among patients receiving chronic systemic corticosteroids, infiltrates may represent Aspergillus pneumonia.

Yellow or green sputum is a reliable indicator of neutrophils in the sputum and suggests bacterial colonization or infection. Culture is usually done in hospitalized patients but is not usually necessary in outpatients. In samples from outpatients, Gram stain usually shows neutrophils with a mixture of organisms, often gram-positive diplococci (Streptococcus pneumoniae), gram-negative bacilli (H. influenzae), or both. Other oropharyngeal commensal organisms, such as Moraxella (Branhamella) catarrhalis, occasionally cause exacerbations. In hospitalized patients, cultures may show resistant gram-negative organisms (eg, Pseudomonas) or, rarely, Staphylococcus.

Diagnosis reference

Prognosis

Severity of airway obstruction predicts survival in patients with COPD. The mortality rate in patients with an FEV1 50% of predicted is slightly greater than that of the general population. If the FEV1 is 0.75 to 1.25 L, 5-yr survival is about 40 to 60%; if < 0.75 L, about 30 to 40%.

More accurate prediction of death risk is possible by simultaneously measuring body mass index (B), the degree of airflow obstruction (O, which is the FEV1), dyspnea (D, which is measured using Modified British Medical Research Council (mMRC) Questionnaire—see Table: Breathlessness Measurement using the Modified British Medical Research Council (mMRC) Questionnaire), and exercise capacity (E, which is measured with a 6-min walking test); this is the BODE index. Also, older age, heart disease, anemia, resting tachycardia, hypercapnia, and hypoxemia decrease survival, whereas a significant response to bronchodilators predicts improved survival. Risk factors for death in patients with acute exacerbation requiring hospitalization include older age, higher Paco2, and use of maintenance oral corticosteroids. (Details for calculating the BODE index are available at Medical Criteria.)

Patients at high risk of imminent death are those with progressive unexplained weight loss or severe functional decline (eg, those who experience dyspnea with self-care, such as dressing, bathing, or eating). Mortality in COPD may result from intercurrent illnesses rather than from progression of the underlying disorder in patients who have stopped smoking. Death is generally caused by acute respiratory failure, pneumonia, lung cancer, heart disease, or pulmonary embolism.

Treatment

  • Smoking cessation

  • Inhaled bronchodilators, corticosteroids, or both

  • Supportive care (eg, oxygen therapy, pulmonary rehabilitation)

COPD management involves treatment of chronic stable disease and treatment of exacerbations. Treatment of cor pulmonale, a common complication of long-standing, severe COPD, is discussed elsewhere.

Smoking cessation is critical in treatment of COPD.

Treatment of chronic stable COPD aims to prevent exacerbations and improve lung and physical function. Relieve symptoms rapidly with primarily short-acting beta-adrenergic drugs and decrease exacerbations with inhaled corticosteroids, long-acting beta-adrenergic drugs, long-acting anticholinergic drugs, or a combination (see Table: Classification and Treatment of COPD).

Treatment of exacerbations ensures adequate oxygenation and near-normal blood pH, reverses airway obstruction, and treats any cause.

Key Points

  • Cigarette smoking in susceptible people is the major cause of COPD in the developed world.

  • Diagnose COPD and differentiate it from disorders that have similar characteristics (eg, asthma, heart failure) primarily by routine clinical information, such as symptoms (particularly time course), age at onset, risk factors, and results of routine tests (eg, chest x-ray, pulmonary function tests).

  • Reductions of FEV1, FVC, and the ratio of FEV1/FVC are characteristic findings.

  • Categorize patients based on symptoms and exacerbation risk into one of 4 groups and use that category to guide drug treatment.

  • Relieve symptoms rapidly with primarily short-acting beta-adrenergic drugs and decrease exacerbations with inhaled corticosteroids, long-acting beta-adrenergic drugs, long-acting anticholinergic drugs, or a combination.

  • Encourage smoking cessation using multiple interventions.

Resources In This Article